NA
ATNM icon

NewEdge Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

NewEdge Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-300
Closed -$2.23K – 3474
2023
Q2 		$2.23K Buy
+300
New +$2.55K ﹤0.01% 3066

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

NewEdge Advisors's ATNM Position: Q3 2023 in Review

NewEdge Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q3 2023, closing a stake of 300 shares — an estimated $2.23K sold.

NewEdge Advisors first reported a position in ATNM in Q2 2023 and held it in 1 quarter. The position peaked at $2.23K in Q2 2023. 58 funds tracked by Wall St. Rank hold ATNM as of Q3 2023.

  • NewEdge Advisors reported no remaining Actinium Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • NewEdge Advisors sold 300 Actinium Pharmaceuticals shares in Q3 2023, an estimated $2.23K.
  • NewEdge Advisors first reported a position in Actinium Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • NewEdge Advisors's Actinium Pharmaceuticals position peaked at $2.23K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.